FIELD: medicine, pharmaceutics. SUBSTANCE: innovation deals with pharmaceutical preparations of ibandronate or its physiologically acceptable salts for oral usage. It represents a medicinal product to treat hypercalcemia, osteoporosis, tumor osteolysis, Paget's disease. Said product is represented by film-covered ibandronate tablets being nonresistant to gastric juice which release, at least, 30% dosage of active substance at contact with aqueous medium at pH ranged 1-7.4 for 2 h. Said medicinal product enables to decrease side effects, to prevent esophagitis, in particular. EFFECT: higher efficiency. 8 cl
Authors
Dates
2002-12-10—Published
1997-04-21—Filed